Filgotinib for Axial spondyloarthritis [ID6594]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Golimumab for treating non-radiographic axial spondyloarthritis (TA497)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 10 January 2018
Ixekizumab for treating axial spondyloarthritis (TA718)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 July 2021
Neuro-Cells stem-cell treatment for traumatic spinal cord injury [TSID12048]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Nusinersen for treating spinal muscular atrophy (TA588)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 July 2019
Omaveloxolone for treating Friedreich’s ataxia in people 16 years and over (terminated appraisal) (TA1061)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 6 May 2025
Onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [ID6556]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Onasemnogene abeparvovec for treating spinal muscular atrophy in people 2 years and over [TSID12168]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Percutaneous vertebroplasty and percutaneous balloon kyphoplasty for treating osteoporotic vertebral compression fractures (TA279)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 24 April 2013
Risdiplam for treating spinal muscular atrophy (TA755)Product type:GuidanceProgramme:Technology appraisal guidanceLast updated: 15 December 2023Published: 16 December 2021
Secukinumab for treating non-radiographic axial spondyloarthritis (TA719)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 21 July 2021
Tofacitinib for treating active ankylosing spondylitis (TA920)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 18 October 2023
Troriluzole for spinocerebellar ataxia [ID6456]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Upadacitinib for treating active ankylosing spondylitis (TA829)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 30 September 2022
Upadacitinib for treating active non-radiographic axial spondyloarthritis (TA861)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 1 February 2023